Search

Deciphera Pharmaceuticals LLC has been granted a patent for a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea, which has potential therapeutic value in treating gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and other substances, intended for oral delivery. It also includes claims for methods of treating GIST by administering the compound to patients in need. The patent was filed by Corey Bloom and assigned to Deciphera Pharmaceuticals LLC. [Extracted from the article]

The article focuses on a newly issued patent concerning methods for treating gastrointestinal stromal tumors (GISTs). Topics include the prevalence and genetic mutations associated with GISTs, the role of receptor tyrosine kinases (KIT and PDGFRA) in their oncogenic behavior, and the evolution of treatment strategies from surgical approaches to targeted therapies based on molecular understanding.

The article focuses on the issuance of a patent to Deciphera Pharmaceuticals for new methods of treating gastrointestinal stromal tumors (GIST). Topics include the prevalence and genetic mutations associated with GIST, the evolution of targeted therapies such as imatinib, and the challenges posed by drug resistance due to secondary mutations.

A recent report from Dalian University of Technology in Shenyang, China discusses the case of a 70-year-old male with primary malignant melanoma of the gastroesophageal junction (GEJ) with a KIT gene exon 11 mutation. The patient presented with abdominal discomfort and was found to have a 6-cm ulcerated neoplasm in the GEJ. Despite recommendations for systemic chemotherapy and immunotherapy, the patient did not receive adjuvant therapy and died 36 months after surgery. The research highlights the importance of considering primary malignant melanoma of the GEJ as a differential diagnosis for gastrointestinal malignancies. [Extracted from the article]

A patent application has been submitted for new therapeutic methods to treat acute myeloid leukemia (AML). The method involves using genetically modified T cells to target and kill cancer cells more effectively. By targeting specific molecules expressed in AML cells, the therapy can selectively target cancer cells while preserving healthy cells. The research aims to improve the prognosis for AML patients and address relapse and drug resistance. The patent application describes methods involving editing the genome of stem cells and administering antibodies or immune cells to improve the effectiveness of AML treatment. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The compound is a potential treatment for gastrointestinal stromal tumors (GIST) and other disorders. The patent describes the structure of the compound and its use in pharmaceutical compositions. The inventors claim that the compound, when administered orally, can effectively treat GIST in patients. The patent provides specific methods and formulations for delivering the compound to patients. [Extracted from the article]

A patent has been issued for methods of treating gastrointestinal stromal tumors (GIST) by administering ripretinib or a pharmaceutically acceptable salt thereof. GISTs are rare tumors that occur in the gastrointestinal tract, with mutations in KIT and PDGFRA genes being common. Imatinib is a commonly used treatment, but resistance can develop. The patent describes various dosing regimens for ripretinib in patients whose tumors have progressed or who are intolerant to imatinib. The methods aim to provide effective treatment options for GIST patients. [Extracted from the article]

A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes the use of ripretinib, a tyrosine kinase inhibitor, as a potential treatment for advanced GIST in patients who have progressed from or are intolerant to previous therapies such as imatinib. The patent outlines various dosing regimens for ripretinib and claims that the treatment can provide about 15 months of survival in patients who have received at least 4 lines of prior therapy. [Extracted from the article]

A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes a method of treating advanced GIST by administering ripretinib, a tyrosine kinase inhibitor, to patients who have previously been treated with imatinib. The treatment aims to provide more than 3 months of progression-free survival in patients. The patent also includes various dosage regimens for ripretinib administration. [Extracted from the article]

This patent application discusses the development of amorphous kinase inhibitor formulations and their potential use in treating certain genetic developmental abnormalities and cancers. The focus is on the c-KIT protein, which plays a role in cellular signaling and various cellular processes. The application describes pharmaceutical compositions that contain amorphous forms of the compound, which may have improved pharmacokinetic profiles and fast release. Additionally, the application mentions the need for oral formulations of PDGFRa inhibitors for the treatment of solid and hematological cancers. Specifically, the patent application includes a method of treating gastrointestinal stromal tumors using a tablet formulation containing the compound in amorphous form. [Extracted from the article]

A patent has been issued for a combination therapy for the treatment of gastrointestinal stromal tumor (GIST). The therapy involves the use of a c-KIT inhibitor in combination with an inhibitor of the MAPKAP kinase signaling pathway. The combination has been shown to lead to cell death, apoptosis, and prolonged cell stasis of GIST cells, as well as enhanced tumor regression in vivo. The therapy is particularly effective for GIST patients who are resistant to imatinib treatment. [Extracted from the article]

A patent application is currently being reviewed for a compound called 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluoropheyl)-3-Phenylurea, which is being developed as a potential treatment for various disorders, including cancer. The application describes the structure of the compound and its potential use in pharmaceutical compositions. The inventors emphasize the need for oral formulations of inhibitors for certain genes associated with cancer. The composition described in the application is specifically for treating gastrointestinal stromal tumors and includes a solid dispersion of the compound along with other ingredients. The application provides detailed information about the composition and its use in treating these tumors. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for a compound called (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The compound is a potential treatment for gastrointestinal stromal tumors (GIST) and other disorders. The patent describes the structure of the compound and its use in pharmaceutical compositions. The inventors claim that the compound, when administered orally, can effectively treat GIST in patients. The patent provides specific methods and formulations for delivering the compound to patients. [Extracted from the article]

The USPTO has published a patent application for a pharmaceutical composition used in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The composition includes a compound represented by Formula (I) and various substances such as hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, lactose monohydrate, crospovidone, silicon dioxide, and magnesium stearate. The patent application also discusses the importance of tyrosine phosphorylation in cellular signaling and its role in various cellular processes. For more information, readers are advised to consult the full patent application. [Extracted from the article]

A recent report from the University of Brescia in Italy discusses the rare occurrence of primary co-occurrence of gonadal and extragonadal central nervous system (CNS) germ cell tumors (GCTs). The researchers reviewed data from 29 patients with CNS GCTs and identified 7 patients with both testicular and CNS GCTs. The average age at tumor diagnosis was 17 years, and genetic factors were found to play a significant role in the development of these tumors. Further research is needed to understand the molecular mechanisms of oncogenesis in these patients. [Extracted from the article]

10x Genomics, a leader in single cell and spatial biology, has announced the availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel for immuno-oncology applications. These products expand the Xenium single cell spatial analysis menu and were developed based on customer feedback. 10x Genomics plans to release more products for Xenium in the future to meet the specific research needs of their customers. [Extracted from the article]

A patent application has been filed for methods of treating gastrointestinal stromal tumors (GIST) using ripretinib. GISTs are rare tumors in the gastrointestinal tract, often caused by mutations in the KIT or PDGFRA genes. Ripretinib is being investigated as a potential treatment for patients who have developed resistance to imatinib, a commonly used drug for GIST. The methods involve orally administering ripretinib tablets at varying doses depending on the patient's previous treatments and tumor progression. The patent application also includes methods for managing side effects of ripretinib. [Extracted from the article]

A patent application has been filed for methods of treating gastrointestinal stromal tumors (GIST) using ripretinib. GISTs are rare tumors in the gastrointestinal tract, often caused by mutations in the KIT or PDGFRA genes. Imatinib is a common treatment for GIST, but some patients become resistant to it. Ripretinib is being studied as a potential treatment for patients who have progressed on or cannot tolerate imatinib. The methods involve orally administering ripretinib at different doses based on the patient's previous treatments and tumor progression. The goal is to achieve at least 5 months of progression-free survival. The patent application provides more information and claims that can be found at the provided URL. [Extracted from the article]

A patent application has been submitted for a new method of treating advanced gastrointestinal stromal tumors (GISTs) using a drug called ripretinib. GISTs are rare tumors in the gastrointestinal tract, often caused by mutations in specific genes. The application outlines the use of ripretinib tablets, taken orally at different doses depending on the patient's condition. The goal of the treatment is to achieve at least 5 months of progression-free survival. The patent application provides detailed information on the dosages and administration protocols for ripretinib in various scenarios, offering potential new treatment options for patients with GISTs. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent was filed by inventors from Deciphera Pharmaceuticals LLC and published online on March 5, 2024. The compound is a c-KIT inhibitor and has potential therapeutic value in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent is assigned to Deciphera Pharmaceuticals LLC and was filed by inventors Corey Bloom, Scott Bone, Fred Jordan, and Michael D. Kaufman. The compound is a c-KIT inhibitor and has potential therapeutic value in the treatment of gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea. This compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions are intended for oral delivery and have good therapeutic properties. The patent was filed by Deciphera Pharmaceuticals LLC and published in February 2024. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. This compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. The patent was filed by Deciphera Pharmaceuticals LLC and published in December 2023. [Extracted from the article]

Deciphera Pharmaceuticals LLC has been issued a patent for compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent describes the compound's structure and its potential use in pharmaceutical preparations. The compound is a c-KIT inhibitor and may have therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent also mentions the link between mutations in the PDGFRa gene and various solid and hematological cancers, and the need for oral formulations of PDGFRa inhibitors. [Extracted from the article]

A patent has been issued for compositions of a compound called 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. The patent was filed by inventors from Deciphera Pharmaceuticals LLC and published online on December 19, 2023. The compound is a broad-spectrum c-KIT inhibitor and has potential therapeutic value in the treatment of refractory gastrointestinal stromal tumors (GIST) and other disorders. The patent describes pharmaceutical compositions containing the compound and one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions aim to provide stable oral formulations with good therapeutic properties. [Extracted from the article]